FDA Approves Amgen's Parsabiv(TM) (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis
THOUSAND OAKS, Calif., Feb. 7, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) ... Biopharmaceuticals, Endocrinology, FDA Amgen, Parsabiv, Etelcalcetide, hyperparathyroid
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Dialysis | Endocrinology | Food and Drug Administration (FDA) | Hemodialysis | Hyperparathyroidism | Marketing | Pharmaceuticals